Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease that is characterized by a progressive loss of lung function. Genetic and environmental factors compromise the epithelial cells of the lung, leading to pulmonary fibrosis over time. DILIsym Services is leveraging our experience in modeling liver fibrosis in non-alcoholic fatty liver disease with NAFLDsym® to simulate lung fibrosis and other aspects of IPF. There is substantial effort within the pharmaceutical industry to develop effective treatments for IPF, and we believe predictions with QSP modeling software like IPFsym will make the clinical development process more efficient.
IPFsym will include key pathophysiologic mechanisms and clinical aspects of IPF, such as lung fibrosis, alveolar epithelial injury and tests of lung function (e.g., forced vital capacity–FVC). IPFsym will also include the ability to simulate disease progression and inter-patient variability in pathophysiologic and clinical characteristics with SimPops®.
The development of IPFsym is being sponsored by a pharmaceutical company, and it will be widely available via licensing and consulting for the broader pharmaceutical industry by 2021. Join our mailing list to stay up to date with the software release, webinars, and more!